ICRA reaffirms Thirumalai Chemicals at BBB, outlook Negative
Thirumalai Chemicals (TIRUMALCHM) said ICRA has reaffirmed its credit rating at BBB with a negative outlook. The company is valued at about ₹1,480 crore.
What happened
Thirumalai Chemicals (TIRUMALCHM) told the exchanges on 17 November 2026 at 07:21 PM that ICRA has reaffirmed its credit rating at BBB with a negative outlook.
Company snapshot
Thirumalai Chemicals is a small-cap company, with a market value of about ₹1,480 crore.
The stock last traded at ₹122.8, against a 52-week range of ₹113.1–₹261.2 (53.0% below the high).
Before this filing the shares had moved −13.8% over the month and −23.1% over three months. Average daily turnover over the last 20 sessions was about ₹3.92 crore.
Promoters held 37.13% at the end of Q2 FY27. Foreign institutions owned 1.39% and domestic institutions 6.72%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 445 | -33.4 | -3.07 |
| Q3 FY26 | 416 | -46.6 | -3.92 |
| Q4 FY26 | 424 | -28 | -2.32 |
| Q1 FY27 | 547 | -43.7 | -3.62 |
| Q2 FY27 | 596 | -34.3 | -2.85 |
What history shows
This is not the company's first credit rating disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Market-wide, 1,480 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
- Thirumalai Chemicals reports Q2 net loss of Rs. 34 crore despite 35% revenue surge
- Thirumalai Chemicals issues update on significant event
- Thirumalai Chemicals receives ₹10.62 lakh GST show cause notice for FY24
- Thirumalai Chemicals Q2 FY27 Unaudited Results Published
- Thirumalai Chemicals Q2FY27 Results: Net loss widens to ₹34 crore on higher revenue
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.